JP2018521127A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018521127A5 JP2018521127A5 JP2018520374A JP2018520374A JP2018521127A5 JP 2018521127 A5 JP2018521127 A5 JP 2018521127A5 JP 2018520374 A JP2018520374 A JP 2018520374A JP 2018520374 A JP2018520374 A JP 2018520374A JP 2018521127 A5 JP2018521127 A5 JP 2018521127A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- disorder
- composition according
- disease
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 25
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 208000035475 disorder Diseases 0.000 claims 15
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 10
- 229940079593 drug Drugs 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 10
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims 5
- 230000005021 gait Effects 0.000 claims 5
- 229960001344 methylphenidate Drugs 0.000 claims 5
- 239000003368 psychostimulant agent Substances 0.000 claims 5
- 208000009575 Angelman syndrome Diseases 0.000 claims 4
- 230000001054 cortical effect Effects 0.000 claims 3
- 230000006735 deficit Effects 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 230000002360 prefrontal effect Effects 0.000 claims 3
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 2
- ZXRVKCBLGJOCEE-UHFFFAOYSA-N Gaboxadol Chemical compound C1NCCC2=C1ONC2=O ZXRVKCBLGJOCEE-UHFFFAOYSA-N 0.000 claims 2
- AZVPADMEIMLODT-UHFFFAOYSA-N propan-2-yl 2-phenyl-2-piperidin-2-ylacetate Chemical compound C=1C=CC=CC=1C(C(=O)OC(C)C)C1CCCCN1 AZVPADMEIMLODT-UHFFFAOYSA-N 0.000 claims 2
- 229940094659 Dopamine reuptake inhibitor Drugs 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 239000000221 dopamine uptake inhibitor Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229960003433 thalidomide Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021018221A JP7350794B2 (ja) | 2015-07-08 | 2021-02-08 | 前頭前皮質プロセシング疾患、歩行及び四肢障害の治療 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/793,829 US9307942B2 (en) | 2011-05-19 | 2015-07-08 | Treatment for cerebral palsy gait impairment |
| US14/793,829 | 2015-07-08 | ||
| US14/881,516 | 2015-10-13 | ||
| US14/881,516 US9333198B2 (en) | 2011-05-19 | 2015-10-13 | Treatment for cerebral palsy gait impairment |
| US14/971,325 US9408838B2 (en) | 2011-05-19 | 2015-12-16 | Treatment for cerebral palsy gait impairment |
| US14/971,325 | 2015-12-16 | ||
| US15/075,375 US9682073B2 (en) | 2011-05-19 | 2016-03-21 | Pre-frontal cortex processing disorder gait and limb impairments treatment |
| US15/075,375 | 2016-03-21 | ||
| PCT/US2016/037367 WO2017007577A1 (en) | 2015-07-08 | 2016-06-14 | Pre-frontal cortex processing disorder, gait and limb impairment treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021018221A Division JP7350794B2 (ja) | 2015-07-08 | 2021-02-08 | 前頭前皮質プロセシング疾患、歩行及び四肢障害の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018521127A JP2018521127A (ja) | 2018-08-02 |
| JP2018521127A5 true JP2018521127A5 (enExample) | 2019-06-20 |
| JP6930969B2 JP6930969B2 (ja) | 2021-09-01 |
Family
ID=57686013
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018520374A Active JP6930969B2 (ja) | 2015-07-08 | 2016-06-14 | 前頭前皮質プロセシング疾患、歩行及び四肢障害の治療 |
| JP2021018221A Active JP7350794B2 (ja) | 2015-07-08 | 2021-02-08 | 前頭前皮質プロセシング疾患、歩行及び四肢障害の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021018221A Active JP7350794B2 (ja) | 2015-07-08 | 2021-02-08 | 前頭前皮質プロセシング疾患、歩行及び四肢障害の治療 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP3319603B1 (enExample) |
| JP (2) | JP6930969B2 (enExample) |
| CN (1) | CN108025003B (enExample) |
| CA (1) | CA2991529C (enExample) |
| MX (1) | MX2017016910A (enExample) |
| WO (1) | WO2017007577A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2991529C (en) * | 2015-07-08 | 2021-01-05 | Gilrose Pharmaceuticals, Llc | Pre-frontal cortex processing disorder, gait and limb impairment treatment |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2157880A (en) | 1937-01-22 | 1939-05-09 | Electrical Res Prod Inc | Recording system |
| US2507631A (en) | 1944-01-19 | 1950-05-16 | Ciba Pharm Prod Inc | Pyridine and piperidine compounds and process of making same |
| US4145083A (en) | 1977-06-17 | 1979-03-20 | Urban Frank K | Therapeutic chair for cerebral palsy child |
| US4844075A (en) | 1984-01-09 | 1989-07-04 | Pain Suppression Labs, Inc. | Transcranial stimulation for the treatment of cerebral palsy |
| GB9120306D0 (en) | 1991-09-24 | 1991-11-06 | Graham Herbert K | Method and compositions for the treatment of cerebral palsy |
| US6355656B1 (en) | 1995-12-04 | 2002-03-12 | Celgene Corporation | Phenidate drug formulations having diminished abuse potential |
| US5908850A (en) | 1995-12-04 | 1999-06-01 | Celgene Corporation | Method of treating attention deficit disorders with d-threo methylphenidate |
| US6121261A (en) | 1997-11-19 | 2000-09-19 | Merck & Co., Inc. | Method for treating attention deficit disorder |
| RU2185106C1 (ru) | 2001-07-12 | 2002-07-20 | Свадовский Александр Игоревич | Способ нейрохирургического лечения детского церебрального паралича |
| US7973057B2 (en) * | 2003-09-17 | 2011-07-05 | The United States Of America As Represented By The Department Of Health And Human Services | Thalidomide analogs |
| US8952895B2 (en) * | 2011-06-03 | 2015-02-10 | Apple Inc. | Motion-based device operations |
| US20050215521A1 (en) | 2003-12-22 | 2005-09-29 | Karim Lalji | Modafinil combination therapy for improving sleep quality |
| US20050182097A1 (en) | 2003-12-30 | 2005-08-18 | Zeldis Jerome B. | Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases |
| AU2006204699B2 (en) * | 2005-01-13 | 2012-04-26 | Sirtris Pharmaceuticals, Inc. | Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders |
| EP2338881A1 (en) | 2005-02-23 | 2011-06-29 | Prexa Pharmaceuticals, Inc. | Dopamine transporter inhibitors for use in treatment of movement disorders and other CNS indications |
| CA2686155C (en) * | 2006-05-22 | 2016-11-15 | The Board Of Trustees Of The Leland Stanford Junior University | Pharmacological treatment of cognitive impairment |
| EP1985276A1 (en) | 2007-04-26 | 2008-10-29 | Merz Pharma GmbH & Co. KGaA | Treatment of movement disorders by a combined use of a chemodenervating agent and automated movement therapy |
| US20110270345A1 (en) | 2007-08-11 | 2011-11-03 | Johns Hopkins University | Focal noninvasive stimulation of the sensory cortex of a subject with cerebral palsy |
| MX2011001384A (es) * | 2008-08-06 | 2011-09-27 | Gosforth Ct Holdings Pty Ltd | Composiciones y metodos para tratar trastornos psiquiatricos. |
| WO2011011528A1 (en) * | 2009-07-23 | 2011-01-27 | Musc Foundation For Research Development | Isopropylphenidate for the treatment of attention-deficit/hyperactivity disorder and fatigue-related disorders and conditions |
| WO2011085256A2 (en) * | 2010-01-07 | 2011-07-14 | Vivus, Inc. | Treatment of obstructive sleep apnea syndrome with a combination of a carbonic anhydrase inhibitor and an additional active agent |
| CN102792513A (zh) * | 2010-03-01 | 2012-11-21 | 波士顿电力公司 | 具有平均温度及热点回授之热感测器装置 |
| EP2544688B1 (en) * | 2010-03-02 | 2016-09-07 | President and Fellows of Harvard College | Methods and compositions for treatment of angelman syndrome |
| US8287903B2 (en) | 2011-02-15 | 2012-10-16 | Tris Pharma Inc | Orally effective methylphenidate extended release powder and aqueous suspension product |
| US20140163070A1 (en) | 2012-05-17 | 2014-06-12 | Bruce Roseman | Treatment for cerebral palsy impaired speech in children |
| US9682073B2 (en) * | 2011-05-19 | 2017-06-20 | Gilrose Pharmaceuticals, Llc | Pre-frontal cortex processing disorder gait and limb impairments treatment |
| US8883815B2 (en) | 2011-05-19 | 2014-11-11 | Gilrose Pharmaceuticals, Llc | Treatment for cerebral palsy impaired speech in children |
| WO2012158892A2 (en) * | 2011-05-19 | 2012-11-22 | Bruce Roseman | A method of treating apraxia of speech in children |
| KR20130016127A (ko) * | 2011-08-04 | 2013-02-14 | 의료법인 성광의료재단 | 외상성 뇌손상의 치료 |
| KR102080154B1 (ko) * | 2011-12-08 | 2020-02-21 | 아포스-메디컬 앤드 스포츠 테크놀로지즈 엘티디. | 신경 장애들을 치료하기 위한 장치 |
| EP2705841A1 (en) * | 2012-09-05 | 2014-03-12 | Pharnext | Combinations of nootropic agents for treating cognitive dysfunctions |
| US9305307B2 (en) * | 2013-07-15 | 2016-04-05 | Google Inc. | Selecting content associated with a collection of entities |
| ES2719703T3 (es) * | 2013-11-08 | 2019-07-12 | Noramco Inc | Procedimiento para la preparación de metilfenidato y sus sales farmacéuticas |
| CA2991529C (en) * | 2015-07-08 | 2021-01-05 | Gilrose Pharmaceuticals, Llc | Pre-frontal cortex processing disorder, gait and limb impairment treatment |
-
2016
- 2016-06-14 CA CA2991529A patent/CA2991529C/en active Active
- 2016-06-14 WO PCT/US2016/037367 patent/WO2017007577A1/en not_active Ceased
- 2016-06-14 EP EP16821790.9A patent/EP3319603B1/en active Active
- 2016-06-14 MX MX2017016910A patent/MX2017016910A/es unknown
- 2016-06-14 CN CN201680052229.7A patent/CN108025003B/zh active Active
- 2016-06-14 JP JP2018520374A patent/JP6930969B2/ja active Active
-
2021
- 2021-02-08 JP JP2021018221A patent/JP7350794B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124432T1 (el) | Φαρμακευτικες συνθεσεις που αποτελουν ν-(3,5-διμεθοδυφαινυλ)-ν'-(1-μεθυλαιθυλ)-ν-[3-(1--μεθυλ-1η-πυραζολ-4-υλ)κινοοξαλιν-6-υλ]αιθανο-1,2-διαμινη | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| FI3265084T3 (fi) | Brutonin tyrosiinikinaasin estäjän lääkeformulaatioita | |
| MX383665B (es) | Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer. | |
| JP2016517883A5 (enExample) | ||
| WO2017022962A8 (ko) | Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물 | |
| EA202091597A1 (ru) | Способы и композиции для лечения апноэ сна | |
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| RU2011152105A (ru) | Составы таблеток 3-цианохинолина и их применение | |
| MX2022002196A (es) | Composición de liberación retardada de niclosamida y uso antiviral de la misma. | |
| JP2017105861A5 (enExample) | ||
| CL2018000430A1 (es) | Compuesto de hidroxitriazina y uso médico relacionado. | |
| WO2016040169A3 (en) | Mucolytic agents for use in tretaing pulmonary sarcoidosis | |
| JP2018199643A5 (enExample) | ||
| MX2022004382A (es) | Metodos para promover la produccion de scfa por microbiota intestinal. | |
| JP2018521127A5 (enExample) | ||
| RU2020120876A (ru) | Фармацевтическая композиция, содержащая антагонист минералокортикоидных рецепторов, и ее применение | |
| JP2019529569A5 (enExample) | ||
| EA202193190A1 (ru) | Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов | |
| JP2015516452A5 (enExample) | ||
| RU2019110264A (ru) | Циклическое соединение | |
| WO2019004788A3 (ko) | 브라우쏘칼콘 a를 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 약학 조성물 | |
| MX2019014201A (es) | Composicion farmaceutica y forma de dosificacion farmaceutica que comprenden (e)-4-(2-(aminometil)-3-fluoroaliloxi)-n-ter-butilbenza mida, proceso para su preparacion, metodos de tratamiento y usos de las mismas. | |
| HRP20241548T1 (hr) | Formulacije stimulansa tripulsnog oslobađanja | |
| JP2010526884A5 (enExample) |